Sponsor Overview
Explore verified public information about Kura Oncology, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Kura Oncology may provide patients with access to investigational drugs through Expanded Access/Compassionate Use Programs when there is sufficient evidence of the safety profile and clinical activity of the investigational drug to support its use in a particular circumstance.”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 2 supporting sources.
Conditions: Acute Lymphoblastic Leukemia, With Appropriate Mutations, Acute Myeloid Leukemia, With NPM1 Mutations
Conditions: HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.